May 30, 2003
GlaxoSmithKline will award research grants from $25,000 to $150,000 ($500,000 total) "for innovative HIV/AIDS drug research in recognition of the need to produce new alternatives and hope in the fight against the HIV/AIDS pandemic." These grants "are intended to further the development of inventive treatments for HIV/AIDS, including: therapies aimed at treating infection; prophylactic vaccines; or microbicides designed to prevent transmission of the virus." Applications will be judged by a panel of outside experts; recipients will be announced at the ICAAC conference in September 2003; and the grants will be paid by November 1. There is no obligation to license resulting technologies to Glaxo.
For more information and application forms, visit www.dddresearchgrant.com or call 888-527-6935.
Copyright 2003 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.
ISSN # 1052-4207
Back to the AIDS Treatment News May 30, 2003 contents page.